Rallybio (RLYB) Non Operating Investment Income (2022 - 2026)
Rallybio (RLYB) posted Non Operating Investment Income of -$17000.0 for Q1 2026, down 183.33% sequentially from -$6000.0 in Q4 2025, and up 19.05% YoY from -$14280.0 in Q1 2025.
Rallybio (RLYB) Non Operating Investment Income (2022 - 2026) Analysis & Trends
Rallybio has reported Non Operating Investment Income for 5 years, with the latest figure at -$17000.0 in Q1 2026.
- Quarterly Non Operating Investment Income rose 19.05% year-over-year to -$17000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$46000.0 (down 138.98% YoY) and the FY2025 annual result came in at -$50000.0, down 194.34% from the prior year.
- Non Operating Investment Income slipped to -$17000.0 in Q1 2026 per RLYB's latest filing, from -$6000.0 in the prior quarter.
- Over five years, Non Operating Investment Income peaked at $240000.0 in Q3 2024 and troughed at -$249000.0 in Q2 2022.
- A 5-year average of $62.5 and a median of -$19000.0 in 2025 frame the typical range for Non Operating Investment Income.
- The widest YoY moves for Non Operating Investment Income: up 275.0% in 2024, down 156.21% in 2024.
- Over 5 years, Non Operating Investment Income stood at $220000.0 in 2022, then grew by 1.36% to $223000.0 in 2023, then plunged by 145.29% to -$101000.0 in 2024, then surged by 94.06% to -$6000.0 in 2025, then tumbled by 183.33% to -$17000.0 in 2026.
- According to Business Quant data, Non Operating Investment Income over the past three periods registered -$17000.0, -$6000.0, and $7000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Mar 31, 2026 | -17,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Dec 31, 2025 | -6,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -30,000.00 |
| Mar 31, 2025 | -21,000.00 |
| Mar 31, 2025 | -21,000.00 |
| Dec 31, 2024 | -101,000.00 |
| Dec 31, 2024 | -101,000.00 |
| Sep 30, 2024 | 240,000.00 |
| Sep 30, 2024 | 240,000.00 |
| Mar 31, 2024 | -86,000.00 |
| Mar 31, 2024 | -86,000.00 |
| Dec 31, 2023 | 223,000.00 |
| Dec 31, 2023 | 223,000.00 |